什么七月 2026 投票做了什么——还有什么悬而未决
药剂调配咨询委员会于 7 月召开会议 23 和 24, 2026 考虑提名列入的七种肽 503原料药清单 — 允许国家许可的医生和药剂师使用没有适用的 USP 专论且不是已批准药品成分的散装物质的肯定清单. 在下面 21 病死率 216.23(c), FDA 评估四件事: 物质的物理和化学特性, 其在复合产品中的使用引起的安全问题, 有效性或不存在的证据, 以及复合药物的历史用途.
FDA 职业人员名单公布 6月简报文件 29, 2026 建议不要添加七项中的任何一项. 委员会对六项内容投了相反的票.
|
肽 (评估游离碱和乙酸盐形式) |
审查建议用途 |
报告投票 |
委员会成果 |
|---|---|---|---|
|
BPC-157 |
溃疡性结肠炎 |
8–6, 1 弃权 |
推荐纳入 |
|
关键PV值 |
伤口愈合和炎症状况 |
8–6, 1 弃权 |
推荐纳入 |
|
TB-500 |
伤口愈合 |
8–6, 1 弃权 |
推荐纳入 |
|
c-字 |
肥胖和骨质疏松症 |
7–5, 2 弃权 |
推荐纳入 |
|
别听 |
脑缺血, 偏头痛, 三叉神经痛 |
8–5, 1 弃权 |
推荐纳入 |
|
埃皮塔隆 |
失眠 |
7–4, 1 弃权 |
推荐纳入 |
|
埃米特肽 (DSIP) |
阿片类药物戒断, 慢性失眠, 发作性睡病 |
6–7, 1 弃权 |
不推荐 |
据报道的计票结果 RAPS 和其他覆盖七月的网点 2026 PCAC肽投票.
FDA 做了什么: 召集委员会, 发布简报文件, 并收到了关于六种物质的咨询建议.
FDA 未做的事情: 将任何肽添加到 503A 散装列表中, 授权任何混合, 或批准的任何产品. 将物质添加到列表中需要通知和评论规则制定, 尚未得出结论的. 所有七种肽的监管地位均未因投票而改变.
另外两个事实使这件事不再是一个封闭的故事. FDA 宣布将于 2 月底前召开后续咨询委员会会议 2027 审查其他肽, 据报道包括 GHK-Cu, 黑色素II, 抗菌肽 (LL-37), 二十六乙酸酯, 和聚乙二醇化机械生长因子. 而在七月 2026 FDA 撤回了其 2021 引用 rDNA 来源上市药物的高纯度合成肽药物产品指南, 说它不再反映当前的科学思维, 同时表示打算重新发行. 框架正在移动, 不解决.
综合组织的实际后果: FDA 的具体肽清单结果远不如应用于肽质量数据的证据标准重要. 该标准现已在公共文件中可见, 这与程序将面临的最终问题是否是复合请愿书的标准相同, 新药研究申请, 或供应商资质审核.
为什么分歧主要是关于文书工作
阅读 FDA 的简报材料，就会发现一种在关注选票统计的报道中很容易被忽视的模式. 该机构对表征的反对并不是因为这些肽无法表征. 他们发现所提交的包裹并没有体现出它们的特征.
这 Bass 发布的 FDA 简报文件分析, 浆果 & 西姆斯 总结核心发现: 除非充分确定物质的化学特性，否则无法制定有意义的质量标准. FDA 工作人员报告说，文献和商业来源经常以相同的通用名描述物质，尽管氨基酸序列存在差异, 或者没有澄清该材料是否是游离碱, 盐, 或酯 - 并指出同一活性部分的不同盐和酯形式在物理化学方面可能表现不同, 毒理学的, 和药代动力学术语.
BPC-157案例是最鲜明的例证. FDA 报告称，遇到以单一通用名称销售的多种含有不同活性部分的物质, 并观察到通用名称不遵循既定的化学命名惯例. 可能有, 该机构表示, 没有可靠的依据来假设给定的名称总是标识相同的结构和形式.
整个系列中又出现了三个缺陷:
-
关键质量属性测试很薄弱. 提名和公共信息经常缺乏有关肽杂质的数据, 聚集体, 微生物质量, 和细菌内毒素——均与注射剂型相关.
-
方法细节不够充分. FDA 表示无法评估身份如何, 纯度, 并从提供的材料中测量杂质. 没有指定色谱方法和支持色谱图的百分比纯度数字不是可评估的声明.
-
杂质工作没有可比性. FDA 想要的是完整的杂质概况——鉴定, 量化, 跨批次和来源的控制——而不是孤立的残值.
安全性讨论中贯穿免疫原性风险, 特别是对于杂质和聚集体未得到充分控制的注射肽.
这四项发现都不需要新颖的科学方法. 它们中的每一个都需要综合组织保留或不保留的记录.
领域 1 - 身份: 你的记录能证明你制造了哪种分子?
身份是 FDA 在评估 503A 批量列表肽时视为基础的领域, 它应用的标准比大多数分析证书所暗示的更严格. 完整分子的单一质量确认可确定分子量. 它没有建立顺序, 它不区分异构体, 并且它没有告诉审稿人该材料是游离碱还是醋酸盐.
没有任何一种技术可以弥补这一差距. 这些框架集中于需要正交方法——单独的技术可能各自独立地失败, 并基于不同的物理原理. EMA 合成肽指南, 例如, 期望至少有两种正交方法支持恒等式.
|
记录检查 |
为什么缺席很重要 |
|---|---|
|
使用仪器通过 LC-MS 或 ESI-MS 获得完整质量, 规定的电离模式和样品制备 |
没有附加方法的质量值无法被复制或质疑, 再现性是结果可用的原因 |
|
多肽合成 序列水平确认——肽图谱, MS/MS 碎片, 或 N 端测序加氨基酸分析 |
仅分子量就与序列变体和位置异构体兼容 |
|
氨基酸分析的氨基酸组成, 每 USP 通则 <1052> 生物技术衍生文章 — 氨基酸分析 |
组成和身份是不同的; 作文结果也锚定了净内容 |
|
盐或游离碱形式的明确声明, 具有抗衡离子身份 |
同一部分的不同形式的理化和药代动力学行为不同 |
|
这 定制肽合成能力 以及针对批次记录的合成路线 |
路线决定杂质谱; 没有它, 审稿人不能 合成肽 判断杂质控制策略是否适合化学 |
最后一项是身份文件和流程文件的交汇点. 通过固相合成和特定偶联策略制成的序列具有可预测的故障模式 - 截断, 删除, 特定残基的差向异构化. 命名路线的记录使这些风险可以评估. 仅列出最终质量的记录并不.
领域 2 — 纯度: 您的号码可以被其他人复制吗?
纯度百分比是典型肽 CoA 中引用最多且信息最少的数字. 它回答了一个问题——样品中紫外线吸收材料的哪一部分对应于主峰——但它对其他几个确定该数字是否有意义的问题保持沉默。.
方法纯度与肽含量不同. 水, 抗衡离子, 残留溶剂, 和不吸收紫外线的污染物位于色谱纯度数据捕获范围之外. 报告的样本 98% 一旦考虑到这些成分，按面积计算的纯度可以含有明显更少的肽质量. 报告两者, 并标记哪个是哪个, 是测量数字和营销数字之间的差异.
|
记录检查 |
为什么缺席很重要 |
|---|---|
|
采用 RP-HPLC 柱的色谱纯度, 坡度, 规定的检测波长和积分参数 |
取决于方法的数据无法在供应商之间或年份之间进行比较 |
|
色谱图本身, 不是一个概括图 |
A shoulder, a late-eluting cluster or a baseline issue is visible in the trace and invisible in the number |
|
Peptide content on a counterion-free, anhydrous basis |
Without it, the reported purity and the actual deliverable mass do not reconcile |
|
Water content and counterion content, measured |
These are the two largest non-peptide contributors by mass in lyophilized material |
|
Peptide quality control and release documentation structured so each batch result links to the specification in force at release |
Release without a versioned specification makes lot-to-lot comparison meaningless |
Lot-to-lot consistency deserves separate mention because it is the claim most often asserted and least often evidenced in custom peptide synthesis documentation. Consistency is not a property of any single batch. It is a property of a data set — which means the evidence is a trend across lots against fixed criteria, not a certificate for the lot in hand. If a supplier cannot produce that trend, “lot-to-lot consistency” in a specification is a statement of intent rather than a demonstrated control.
领域 3 — 分析方法: 审稿人可以重建你的方法吗?
FDA’s stated complaint was not that the analytical results were wrong. It was that the materials did not provide enough method-specific information to judge whether the results were reliable. That distinction matters, because it means the fix is descriptive rather than experimental.
For each method used to support a specification, a reviewer needs enough detail to understand what was measured and to form a view on whether the method can do what it claims. What a method must demonstrate before its numbers are usable is set out in 我Q2(R2) on the validation of analytical procedures, and the chromatographic parameters an implied method must state are defined in USP <621> Chromatography.
|
记录检查 |
为什么缺席很重要 |
|---|---|
|
Full method description: column chemistry and dimensions, mobile phase, gradient table, flow rate, column temperature, 检测波长 |
An implied method is not a method; a reviewer cannot assess specificity without it |
|
System suitability results for the run |
System suitability is the evidence that the run was fit for purpose before the sample was injected |
|
Representative chromatograms for reference standard, sample and, 相关的, a spiked or stressed sample |
Specificity is demonstrated by what the method resolves, not by assertion |
|
Validation or verification data covering accuracy, 精确, 特异性, linearity and range for the intended use |
Unvalidated numbers cannot support a specification, in any regulatory context |
|
Peptide analytical testing services scope stated explicitly, with a clear line between tests performed in-house and tests subcontracted |
Subcontracted testing is normal; undisclosed subcontracted testing is a documentation failure |
|
Reference standard identity, 来源, and qualification record |
Every quantitative result is traceable to a standard, and an unqualified standard undermines all of them |
A useful test: hand the method section to a competent analyst who has never worked on the molecule and ask them to reproduce the run. If they cannot, the section is not finished. This is a lower bar than validation and it catches the majority of real gaps.
领域 4 — 肽杂质谱: FDA 肽清单流程的期望是什么
This is where the July 2026 record is most specific and where threshold numeracy matters most.
Synthetic peptides sit in an unusual regulatory position. The EMA synthetic-peptide guideline states that synthetic peptides are fully or partially excluded from the scope of ICH Q3A and Q3B, ICH Q6A and Q6B, and ICH M7, and instead applies peptide-specific impurity thresholds anchored to the European Pharmacopoeia general monograph. FDA’s synthetic peptide guidance has treated ICH Q3A and Q3B as a general framework with peptide-specific modifications. Either way, the small-molecule impurity table does not apply unchanged, and a program should be able to state which framework it is following and why.
|
框架 |
Report |
Identify |
Qualify or control |
|---|---|---|---|
|
FDA synthetic peptide guidance (2021; withdrawn July 2026, reissue planned) |
— |
Each peptide-related impurity at ≥0.10% of the drug substance |
New specified peptide-related impurity not above 0.5% of the drug substance |
|
FDA revised draft product-specific guidances (July 2026) |
>0.1% |
>0.5% |
Shared impurities at or below the reference-listed-drug level or 1.0%, whichever is higher |
|
>0.1% |
>0.5% |
>1.0% |
Reported tier details vary across secondary summaries of the July 2026 drafts, 和 2021 guidance was withdrawn with a reissue pending — so treat any single number here as framework-specific and verify the current document before you rely on it in a submission. The structural point is stable even though the numbers may shift: peptide-related impurities are governed by their own thresholds, and they are low.
What that means for the peptide impurity profile a program should hold:
|
记录检查 |
为什么缺席很重要 |
|---|---|
|
Related substances reported by a named method down to the reporting threshold, with each peak above it accounted for |
An unlisted peak is an unidentified impurity, and unidentified impurities cannot be qualified |
|
Structural assignment for each impurity above the identification threshold — sequence, modification site, 或两者兼而有之 |
截断, 删除, 差向异构残基, deamidated and oxidized variants each carry different risk and are not interchangeable 多肽生产 |
|
Non-peptide impurities addressed under their own frameworks: ICH Q3C 下的残留溶剂, elemental impurities under ICH Q3D, mutagenic impurities under ICH M7 |
Peptide-related impurities are only one class; a specification that stops there is incomplete |
|
A documented nitrosamine risk assessment covering amines, nitrosating agents and reaction conditions |
This is now an expectation rather than an option, and it applies to reagents as much as to the peptide |
|
Aggregation and higher-molecular-weight species assessed, with the method named |
Aggregates are immunogenicity-relevant and largely invisible to a standard reversed-phase purity method |
|
Batch-to-batch impurity trend data, not a single-lot profile |
Control is demonstrated by stability of the profile over time, which one lot cannot show |
The commercial argument for doing this work before anyone asks is straightforward. Impurity characterization is cheapest at the point when the chemistry is still being adjusted. Once a specification is fixed and a program has committed to a supplier, an unidentified impurity at 0.6% becomes a deviation, a retest, and possibly a reformulation of the control strategy. The peptide impurity profile FDA expects under current guidance is not new in kind; the July 2026 record simply made it unusually visible.
领域 5 — 采购: 你能把一批产品带回到它的氨基酸吗?
This is the domain that received the least public attention and carries the most unexamined risk. Compounding-list coverage focused on the peptide. FDA’s characterization questions, and the general expectations for peptide starting materials, reach all the way back to the amino acid derivatives, 树脂, and solvents that went into the synthesis.
USP 通则 <1504> addresses quality attributes of starting materials for the chemical synthesis of therapeutic peptides and is intended to be used alongside the peptide drug substance chapter. It names the non-amino-acid-derivative impurity risks these materials carry: residual solvents and reagents left over from their own preparation, elemental impurities, and transmissible spongiform encephalopathy or bovine spongiform encephalopathy risk. ICH Q7 Chapter 7 sets the materials management baseline — each raw material batch recorded with manufacturer name, 身份, quantity, supplier, and supplier control number, purchased against agreed specifications, and traceable into the batches where it was used.
|
记录检查 |
为什么缺席很重要 |
|---|---|
|
Approved specification and CoA for every critical raw material batch, reviewed against that specification before use |
A CoA filed without review is a document, not a control |
|
Supplier qualification records including audit or assessment status and a change-notification commitment |
Undisclosed supplier process or site changes are the most common route to an unexplained batch shift |
|
Manufacturer name and supplier control number for each raw material lot, with linkage to the peptide batches in which it was used |
Without forward and backward traceability, a raw material problem cannot be bounded to affected batches |
|
Residual solvent declarations or test results aligned to ICH Q3C |
Solvent carryover from a derivative becomes a peptide impurity |
|
Elemental impurity risk assessment aligned to ICH Q3D, covering contributions from materials, catalysts and equipment |
Metal content in a peptide is usually inherited, not introduced |
|
TSE/BSE statements for any animal-derived or potentially animal-derived material, with species and origin |
Origin questions surface late and are expensive to answer retrospectively |
Two practical points. 第一的, the manufacturer of a critical material should always be known and documented — not just the distributor. Identity of the actual producer is what makes a supply risk assessable. 第二, change control is the part of supplier qualification most often left verbal. A written commitment to notify before a process or site change is what converts a supplier relationship into a managed one. Programs that outsource synthesis support with a peptide CRO services partner inherit that partner’s supply chain, so the same traceability questions apply one layer further up.
领域 6 — 预期用途: 您的规格是否符合给药途径和剂量?
Here the July 2026 record offers the clearest lesson about specifications generally. Every one of the seven peptides was evaluated for a specific proposed use. The committee that reviewed BPC-157 considered ulcerative colitis. Semax was reviewed for cerebral ischemia, 偏头痛, and trigeminal neuralgia. Emideltide was assessed for opioid withdrawal, 慢性失眠, and narcolepsy, and FDA’s stated concern included the absence of safety data for the subcutaneous route in particular.
That is not a detail of the compounding framework. It is the general principle: the specification follows the intended use, the route, and the dose — not the molecule name in isolation.
The EMA synthetic-peptide guideline makes the same point structurally. It applies to synthetic peptides used in a medicinal product, distinguishes research-use-only material from pharmaceutical material, expects the counterion to be identified with its stoichiometry, and expresses peptide content on a counterion-free, anhydrous basis within a mass-balance approach to content and purity. A material that is entirely adequate for in vitro screening can be inadequate for an injectable formulation, and the specification is where that difference lives.
|
记录检查 |
为什么缺席很重要 |
|---|---|
|
Intended use stated explicitly on the specification: research use, further manufacturing, or a defined clinical route |
Specification content cannot be justified without the use it is written for |
|
Route of administration, dose level, and dosing duration recorded where a clinical use is contemplated |
Qualification thresholds and endotoxin limits depend on these inputs |
|
纯度, 内容, 抗衡离子, 水, and residual solvent criteria set to that use rather than to a house default |
A default specification is a specification nobody has justified |
|
Microbiological and endotoxin criteria appropriate to the route, with the test method named |
The endotoxin method and limit differ materially between a non-sterile research reagent and an injectable |
|
A stated position on whether the material supports that use, and what would be required to support a different one |
Programs that never state the boundary tend to cross it by accident |
The last row is deliberately uncomfortable. Being able to say “this material is qualified for X and would need Y before it could support Z” is more useful to a reviewer and a partner than a specification broad enough to permit everything and specific enough to prove nothing. It is also the record most often missing, because it requires a decision rather than a measurement. For teams designing peptide variants toward a target profile, the same logic applies one step earlier — read across the protein engineering lessons for peptide optimization to see how design intent constrains the quality attributes worth tracking from the first batch.
在其他人之前对包裹进行评分
FDA’s four criteria give a program something better than a checklist: they imply a scoring rule that predicts which parts of a documentation package will be challenged. The criterion that receives the most attention publicly is characterization, but the one that sinks petitions is usually the weakest link rather than the average.
|
领域 |
Evidence a reviewer can act on |
Typical weak point |
|---|---|---|
|
身份 |
Two orthogonal methods, salt form declared, route recorded |
Single intact mass standing in for sequence confirmation |
|
纯度 |
Method-qualified figure plus counterion-free content, water and counterion measured |
A percentage with no method and no content basis |
|
Analytical methods |
Full method description, system suitability, validation data, representative traces |
Implied methods and summary chromatograms |
|
Impurity profiles |
Every peak above the threshold assigned; non-peptide classes covered; trend data |
Isolated residual values presented as a profile |
|
采购 |
Manufacturer named, lot traceability into batches, change-control commitment |
Distributor name only, verbal change control |
|
Intended use |
Use and route stated, criteria justified, boundary stated |
House-default specification |
The scoring discipline that matters is not adding up the good rows. It is identifying the one domain where the program would have nothing to say if asked, and closing that gap first. Work on the strong domains is comfortable and mostly adds documentation weight; work on the weak domain is what changes the outcome.
A second practical step is to convert these tables into a vendor questionnaire and answer it as though it were being asked by someone else. Most programs find that the material they can produce readily — chromatograms, 质谱, CoAs — maps onto the domains they are already strong in, while the domains that depend on deliberate record-keeping, sourcing traceability and intended-use justification, require decisions they have not yet made. That asymmetry is predictable, and it is better found internally than during a review.
None of this depends on how the rulemaking concludes or what the February 2027 committee does with a further set of peptides. The record set described in this peptide documentation checklist is what any peptide program should be able to produce to describe its own material honestly — to a regulator, to a partner conducting due diligence, or to its own quality function during an investigation to which external review is a detail rather than the trigger.
后续步骤
If any of the six domains above came back thin, the useful next move is a technical review of the specific gaps rather than a general quality claim. MOL Changes works with development teams on exactly that: walking through an existing documentation package against identity, 纯度, methodological, impurity, sourcing, and intended-use expectations, and identifying what a lot-specific data package would need to include to close the gap. If that would help your program, ask for a technical feasibility assessment and we will tell you plainly what your current records support, what they do not, and what it would take to get there.
